Also, slide 78 from the EMPA-REG OUTCOME presentation I linked earlier has the following summary:

"Empagliflozin, as used in this trial, for 3 years in 1,000 patients with type 2 diabetes at high CV risk:

• 25 lives saved (82 vs 57 deaths)
• 22 fewer CV deaths (59 vs 37)
• 14 fewer hospitalisations for heart failure (42 vs 28)
• 53 additional genital infections (22 vs 75)"

Perhaps their slogan should be: Saving lives, infecting genitals